Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
mesenchymal stem cell-derived pleiotropic factor
- Development stage
- Phase 1
- Lead developer
- First Affiliated Hospital of Nanchang University
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Administration
- Topical
01
Overview
Mesenchymal stem cell-derived pleiotropic factor (MSC-PF) is an investigational biologic preparation derived from the paracrine secretions (secretome) of mesenchymal stem cells. It is typically produced by collecting the conditioned medium from MSC cultures and processing it into a lyophilized powder. The factor consists of a complex mixture of bioactive cytokines and growth factors, including **Insulin-like Growth Factor-1 (IGF-1)**, **Vascular Endothelial Growth Factor (VEGF)**, **Transforming Growth Factor-beta 1 (TGF-β1)**, and **Hepatocyte Growth Factor (HGF)**. These components act synergistically to promote tissue regeneration, reduce inflammation, and accelerate wound closure by stimulating angiogenesis and the proliferation of dermal fibroblasts and keratinocytes. MSC-PF is primarily being studied as a cell-free alternative to stem cell therapy for the treatment of chronic wounds, severe burns, and postoperative incision complications.
- Other names
- mesenchymal stem cell conditioned medium-derived pleiotropic factorMSC conditioned medium-derived pleiotropic factorMSC-CM-derived pleiotropic factorstem cell-derived bioactivatorMSC secretome-derived pleiotropic factor
Beyond the preview
Go deeper on mesenchymal stem cell-derived pleiotropic factor.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on mesenchymal stem cell-derived pleiotropic factor.